Drug intelligence / Profile preview

Lucid-201

Development stage: Unknown
Lead developer: Quantum BioPharma
Modality: Small Molecules
Administration: Oral

Overview

Lucid-201 is an orally administered, psychedelic-inspired small molecule being developed by Lucid Psycheceuticals, a subsidiary of FSD Pharma, for the treatment of major depressive disorder and other mental health conditions.[5][18] Preclinical data and prior clinical experience with the underlying known molecule support antidepressant potential, and Lucid-201 (also referred to as Lucid-PSYCH) is positioned as a next-generation psychoactive agent intended to deliver clinical efficacy with a differentiated safety and tolerability profile.[1][5][18] A first-in-human, double-blind, single-ascending-dose Phase 1 trial in healthy adults (LUCID-201-001) is underway to characterize safety, tolerability, pharmacokinetics, and pharmacodynamic effects of single oral doses.[13][16][17][18]

Other names: Lucid-Psych

Beyond the preview

Go deeper on Lucid-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lucid-201.

Explore the full profile